This revised proposal details a 4-year training program for the development of an academic career in cancer biology. Having recently completed clinical training in medical oncology, the Principal Investigator (PI) will use this dedicated period to acquire the knowledge and skills necessary to become an independent researcher. The PI will be mentored by a leading cancer biologist, Dr. Harold Varmus, who has trained numerous productive scientists. The Memorial Sloan-Kettering Cancer Center will provide institutional support. Ample resources and multiple career development activities will be available to help the PI achieve his goals. Research will focus on lung cancer, the leading cause of cancer-related mortality worldwide. The lab has developed a mouse model of lung cancer which shows that the continued expression of activated K-ras is required for the maintenance of lung tumors. This suggests that tumor cell death could be induced by targeting molecules that regulate this process. The studies proposed are designed to elucidate the mechanisms of lung tumor regression. The hypothesis is that lung tumor cells expressing the K-ras oncogene have undergone adaptive changes in gene transcription and/or protein expression such that they require the continued presence of activated K-ras for viability. Preliminary data suggest that major Ras signaling pathways and/or inhibitor of apoptosis proteins (lAPs) are probably involved. To study this further, we will use 2 experimental approaches: the lung cancer mice, and a more flexible model system that the PI has developed in which transformed murine embryonic fibroblasts (MEFs) also display dependence on activated K-ras for tumor survival. Although MEF and lung tumors are derived from different cell types, the MEF tumor regression model phenocopies that seen in the lung, suggesting that shared mechanisms may exist. Findings obtained from studies of MEF tumor regression will be verified in lung tumors.
Specific aims i nclude 1) determining if/which major Ras signaling pathways mediate activated K-ras-dependent tumor maintenance and 2) assessing the impact of lAPs in maintaining tumor survival. The long-range goal is to identify molecular targets to induce apoptosis in human luno cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA097980-04
Application #
7493380
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2005-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2008
Total Cost
$101,596
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Weiss, Jonathan; Sos, Martin L; Seidel, Danila et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93
Gong, Yixuan; Yao, Evelyn; Shen, Ronglai et al. (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4:e7273
Girard, Nicolas; Ostrovnaya, Irina; Lau, Christopher et al. (2009) Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 15:5184-90
Regales, Lucia; Gong, Yixuan; Shen, Ronglai et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-10
Girard, Nicolas; Shen, Ronglai; Guo, Tianhua et al. (2009) Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 15:6790-9
Marks, Jenifer L; Gong, Yixuan; Chitale, Dhananjay et al. (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68:5524-8
Bean, James; Riely, Gregory J; Balak, Marissa et al. (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14:7519-25
Marks, Jenifer L; McLellan, Michael D; Zakowski, Maureen F et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2:e426
Gong, Yixuan; Somwar, Romel; Politi, Katerina et al. (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4:e294
Bean, James; Brennan, Cameron; Shih, Jin-Yuan et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-7

Showing the most recent 10 out of 13 publications